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ABSTRACT 
Patients with atrial fibrillation are associated with a 4-5-fold risk of having a stroke. The most effective 
treatment for atrial fibrillation is to prevent blood clot formation by administering anticoagulant drugs. 
Warfarin is an anticoagulant drug with a narrow therapeutic index, with side effects of bleeding risk. Hence, 
it needs supervision in its use. In this study, the HAS-BLED score was used to measure major bleeding risk 
and as a value representing each risk factor for bleeding. The bleeding risk can be prevented by maintaining 
a warfarin response in the therapeutic range with an INR (International Normalized Ratio) measurement 2-
3. This study was an observational study conducted with retrospective data collection through medical 
records of patients with a primary diagnosis of atrial fibrillation who received oral warfarin anticoagulant 
therapy at Harapan Kita National Heart Center in the period of January-December 2017. There is 40 patients 
sample who met the inclusion criteria. According to the data, in atrial fibrillation patients who received oral 
warfarin therapy, 55% were male patients, while 45% were female patients. Patients with atrial fibrillation 
who got the most oral warfarin therapy were over 40 years old with 90% of the total sample, with the 
highest group in patients aged 50-54 years with 22.5%. The HAS-BLED values arranged from 0-9, the 
percentage of patients who had HAS-BLED values of 0, 1, 2 respectively at 7.5%, 42.5%, 30%. The HAS-
BLED score ≥ 3 showed patients classified as at high risk of bleeding by 20%. The most risk factors based 
on HAS-BLED score from all study samples were 18 patients with abnormal kidney or 45%. The average 
INR score in patients at high risk of bleeding showed that 37.5% had an average INR score in the target 
ratio score of INR 2-3. 
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INTRODUCTION 
Atrial fibrillation is the most common 
type of arrhythmia. Normally, a person 
would have 60 to 100 heartbeats per minute. 
An atrial fibrillation patient, however, would 
have up to 175 heartbeats per minute. Atrial 
fibrillation increases the risk of stroke 4 to 5 
times. The risk of stroke by atrial fibrillation 
increases exponentially by age. Patients aged 
50-59 have a 1.5% chance of having a stroke 
by atrial fibrillation, while patients aged 80-
89 have a much higher risk of 23.5%.1 This is 
reflected in the data acquired from the 
Harapan Kita Hospital for Heart and Arteries, 
which shows the constant yearly increase in 
atrial fibrillation cases: 7.1% in 2010, 9.0% 
in 2011, 9.3% in 2012, and 9.8% in 2013.2 
One of the most important aspects of atrial 
fibrillation treatment is the prevention of 
blood clots, and such is the reason why 
anticoagulant is commonly prescribed.3  
Anticoagulants use as prophylaxis of 
stroke in atrial fibrillation patients can 
decrease stroke risk by 60%.4 The most 
significant side effect of anticoagulants, 
especially warfarin, is hemorrhage risk.5  
In 2010, the HAS-BLED score 
(Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history, Labile 
INR, Elderly, Drugs) was first validated in 
Europe's heart survey. HAS-BLED is a 
scoring system used to measure hemorrhage 
risk, which represents each factor that can 
lead to hemorrhage. This system determines 
the score for each hypertension risk 
(uncontrolled systolic blood pressure > 160 
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mm Hg), kidney function or liver 
abnormalities, previous stroke episode(s), 
hemorrhage history or predispositions, labile 
INR, older patients (aged 65+), common 
drugs and/or the alcohol excess. HAS-BLED 
score is presented on a scale of 0 to 9, with a 
score of ≥3 implicates a higher hemorrhage 
risk. High hemorrhage risk can be prevented 
by maintaining warfarin response within the 
therapeutic span using INR (International 
Normalized Ratio) measurement. INR 
measurement has been deemed an integral 
part of warfarin treatment.6 Warfarin has a 
narrow therapy index as its side effects need 
to be paid close attention to provide effective 
and safe therapy to atrial fibrillation patients. 
 
METHODS 
This research is an observational one: 
research was done using retrospective data 
collection through medical records analysis. 
The researcher went through an evaluative 
study, which was conducted to assess an 
ongoing or a completed program. A 
retrospective approach was made by 
observing past events aimed at determining 
factors pertaining to cause and effect. 
Research and data collection took place 
between February and May of 2018. The 
research population was patients whose 
primary diagnoses were atrial fibrillation; 
these patients were those who were given oral 
warfarin anticoagulant therapy at Harapan 
Kita Nasional Heart Center. Samples were 
chosen based on atrial fibrillation patients' 
medical records at Harapan Kita within the 
January-December 2017 period. Patients 
whose main diagnoses were atrial fibrillation, 
patients who had acquired oral warfarin 
anticoagulant therapy for at least three 
months, male and female patients were 19 
years old and above at the time of data 
collection. 
 
RESULTS AND DISCUSSION 
Patient demographic 
Out of 40 patients, 22 male patients (55%) 
and 18 female patients (45%). Results show 
that coagulation occurs more in male patients 
than in female patients. Some of the factors 
which affect blood coagulation in male 
patients are lifestyle-related: types of food 
consumed, smoking, lack of exercise, and an 
irregular pattern of rest. Results are in line 
with the data that shows that male patients 
acquire more warfarin therapy to prevent and 
decrease the risk of coagulation, resulting in 
a decrease in the risk of stroke in atrial 
fibrillation patients.7 These patients were put 
into six different age groups. 
 
 
Figure 1. Patients based on age groups 
 
Based on the data acquired, atrial fibrillation 
patients who acquired the most oral warfarin 
therapy were patients aged 50-54 (22.5%). In 
total, 90% of patients who acquired the most 
oral warfarin therapy were those above 40 
years of age. The older the patients, the more 
poorly their organs work, resulting in organs 
not functioning properly. Older patients also 
have a higher risk of blood clotting due to 
their organs not functioning correctly, 
resulting in coagulation. Patients within this 
age group need to be closely supervised 
during warfarin prescription due to them 
having a high risk of getting heart disease.8 
 
 
Patients Based on HAS-BLED Scores 
HAS-BLED is a scoring system that 
measures the risk of hemorrhage. HAS-
BLED has been proven in various research to 
identify patients with hemorrhage risk.8 
HAS-BLED represents each hemorrhage risk 
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and determines the score for each 
hypertension risk (uncontrolled systolic 
blood pressure >160 mm Hg), kidney 
function or liver abnormalities, previous 
stroke episode(s), hemorrhage history or 
predispositions, labile INR, older patients 
(aged 65+), common drugs and/or the alcohol 
excess. HAS-BLED score is presented on a 
scale of 0 to 9, with a score of ≥3 implicates 
a higher hemorrhage risk, hence the need to 
conduct a routine assessment on patients with 
such score carefully. Based on the HAS-
BLED scores of the samples obtained 
through the measurement of each risk factor, 
there were eight patients with ≥3 HAS-BLED 
scores (20%). Results showed that kidney 
abnormalities risk factor or kidney 
malfunction and old age (65+) contribute to 
the HAS-BLED scores of these eight patients 
(who have an 87.5% risk of experiencing 
hemorrhage) the most. The results can be 
seen in table 1. 
 
Table 1. Risk factor score percentage based 
on HAS-BLED 3 
Risk factor Score Percentage 
(%) 
Hypertension 4 16 
Kidney abnormality 7 28 
Bleeding History 2 8 
Old age 5 20 
Unstable INR 7 28 
 
Evaluation of Warfarin Dosage Based on 
INR 
INR score is the parameter for measuring 
warfarin dosage accuracy, ensuring that the 
warfarin dosage given is effective and does 
not cause hemorrhage. However, it is to be 
noted that there had been reports that patients 
with a 2-3 INR ratio still have the potential to 
experience hemorrhage. INR test frequency 
was divided into four groups. The number 
and percentage of patients based on INR test 
frequency can be seen in figure 2.  
 
 
Figure 2. The number and percentage of patients 
based on INR test frequency 
 
Based on the data above, it can be seen that 
the highest frequency of INR test is on the 
once-a-month frequency with 62.5%. In this 
category, patients were given INR tests in 3 
consecutive months during their treatment. 
Based on medical records, patients not doing 
INR tests based on the doctor's 
recommendation result from them not 
complying with the therapy procedure. 
Patients' educational, economic, social, and 
psychological backgrounds significantly 
influenced their compliance with the INR 
test. INR observation was done every day 
starting from the first time a patient 
consumed warfarin until INR was within the 
range of 2-3 (INR should be done every two 
days at the very least). INR was then checked 
for 2-3 times a week in 1-2 weeks. If the 
patients were deemed stable, observations 
could then be done once in 4-6 weeks. If 
dosage adjustments were considered to be 
needed, INR observation would be done 
more frequently until stability could be 
achieved. The target INR score was 2-3 
within an effective ratio, which would not 
entail coagulation; dosage would also be a 
safe one that would not give a side effect in 
the form of hemorrhage. For the patients who 
have a high risk of experiencing hemorrhage 
as assessed by HAS-BLED, there should be 
an evaluation on INR test scores during their 
warfarin therapy. The average of patients' 





                                            Jurnal Profesi Medika : Jurnal Kedokteran dan                             
ISSN 0216-3438 (Print). ISSN 2621-1122 (Online)                                                                                        Kesehatan 
 
Vol. 14 No 2 2020 DOI :  http://dx.doi.org/10.33533/jpm.v14i2.1671                                                 135 
 
Table 2. High-risk patients' average INR 
scores 











The table above shows that the average INR 
scores of patients did not meet the 2-3 ratio 
target. Most INR scores were still below 2, 
and this indicates the possibility of 
coagulation still likely to happen. From the 
average warfarin score of 8 patients who had 
a high risk of experiencing hemorrhage, the 
INR score was at 1.99. On the other hand, a 
high risk of hemorrhage is shown in the INR 
score of above 3. From 8 patients, three 
patients had an average INR score within the 
target ratio of 2-3. It can be said that 37.5% 
of atrial fibrillation patients who acquired 
warfarin therapy, who were deemed to have 
a high risk of experiencing hemorrhage 
(based on HAS-BLED), had been given an 
effective and safe warfarin therapy. The other 
62.5% of atrial fibrillation patients who were 
given warfarin therapy, who were put in the 
high-risk hemorrhage group based on their 
HAS-BLED, had not reached the INR 2-3 
ratio to be acquiring the effectiveness of 
warfarin. When starting an anticoagulation 
therapy, it is crucial to assess its risks and 
benefits first for the patients.9 Each abnormal 
INR score cannot become the standard for all 
patients: an individual approach is needed to 
adjust the dosage and discontinuous INR 
observation. The amount of warfarin dosage 
given is based on the INR score, which is 
adjusted to individual dosage. In this 
research, 40 samples were given warfarin in 
the daily dosage range of 1-6 mg. The dosage 




Table 3. Warfarin dosage percentage 
 








Based on the results, the most commonly 
used warfarin dosage was 2 mg, with a 
percentage of 59.2%. Patients simultaneously 
started taking amiodarone, statin, antibiotics, 
or any other drugs known to improve 
warfarin effectiveness. There should be an 
initial consideration on the initial dosage of 
warfarin would be smaller. Patients who had 
used warfarin before the therapy and started 
this treatment (which also used warfarin) 
should also be paid more attention to the 
dosage they would be given. 
 
CONCLUSION 
Based on the results and discussion, it 
can be concluded that there were eight 
patients with HAS-BLED scores of ≥3, 
which were 20% of the samples. They had a 
relatively high risk of experiencing 
hemorrhage. There were 25 patients 
(62.50%) who acquired oral warfarin therapy 
and routine INR test (once a month). 37.5% 
of atrial fibrillation patients who acquired 
warfarin therapy were considered to have a 
high risk of experiencing hemorrhage based 
on their HAS-BLED scores within the INR 2-
3 score target ratio. Patients who were given 
oral warfarin therapy showed improvements 
in their INR scores based on their routine 
INR test results. 
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